新型化疗止吐药罗拉匹坦的药理研究及临床应用

Pharmacological studies of rolapitant and its clinical application

化疗所致恶心呕吐(CINV)是影响肿瘤患者治疗依从性的关键因素。新型神经激肽-1(NK-1)受体拮抗剂罗拉匹坦与其他已批准上市的NK-1拮抗剂不同,可联合其他止吐药用于延迟性CINV,并能避免药物间相互作用。本文简要综述罗拉匹坦的药理作用及其在CINV治疗中的应用进展。

Nausea and vomiting are the major side effects of chemotherapy and the key reason for non-compliance with cancer treatment. Rolapitant, which is new type of neurokinin-1（NK-1） receptor antagonist, is unlike other approved agents in this class, it can be in combination with other antiemetic agents for the prevention from delayed chemotherapy-induced nausea and vomiting （CINV）. Rolapitant may be beneficial for some patients where drug-drug interaction should ideally be avoided. This review describes the pharmacological action and application status of rolapitant in CINV treatment.